Cogent Biosciences, Inc. COGT Depreciation Expense — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s depreciation expense — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s depreciation expense — operating income?
- Cogent Biosciences, Inc. (COGT) reported depreciation expense — operating income of $626K in Q1 2026.
- How has Cogent Biosciences, Inc.'s depreciation expense — operating income changed year-over-year?
- Cogent Biosciences, Inc.'s depreciation expense — operating income decreased by 2.2% year-over-year, from $640K to $626K.
- What is the long-term trend for Cogent Biosciences, Inc.'s depreciation expense — operating income?
- Over 3 years (2022 to 2025), Cogent Biosciences, Inc.'s depreciation expense — operating income has grown at a 44.9% compound annual growth rate (CAGR), from $842K to $2.56M.
- What does depreciation expense — operating income mean?
- This metric represents the non-cash depreciation expense specifically allocated to the company's operational segments as reflected in the calculation of operating income or loss. It captures the systematic allocation of the cost of tangible assets used in research, development, or commercial operations over their useful lives. Monitoring this expense helps investors understand the capital intensity of specific business units and the impact of asset aging on the company's core profitability.